Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Merck’s KEYNOTE-B96 trial signals survival benefit in platinum-resistant ovarian cancer, but MRK stock dips
Merck's KEYNOTE-B96 trial shows survival benefit in ovarian cancer. See what it means for patients, pipeline, and MRK stock. Read full analysis now.
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.
How SOPHiA GENETICS’ AI Digital Twins could transform oncology treatment forever
Find out how SOPHiA GENETICS’ new AI-powered Digital Twins could revolutionize cancer care and reshape global oncology economics.
Inside Thermo Fisher Scientific’s plan to harness OpenAI for faster, smarter biotech innovation
Find out how Thermo Fisher Scientific plans to use OpenAI’s generative AI to revolutionize research speed, accuracy, and discovery across life sciences.
Hypertension breakthrough: Scienture launches first FDA-approved liquid losartan Arbli through U.S. distributors
Discover how Scienture’s Arbli is redefining hypertension treatment as the first FDA-approved liquid losartan and what it signals for SCNX investors.
Tempus joins forces with Whitehawk Therapeutics to power next-gen biomarker-based oncology trials
Find out how Tempus and Whitehawk are using AI and real-world data to transform biomarker-driven oncology—discover the collaboration’s science and market impact.
Can Genentech’s $50 direct-to-patient Xofluza launch reshape access to flu antivirals in 2025?
Genentech slashes Xofluza price by 70% in a direct-to-patient launch with Amazon, Cost Plus, and Alto Pharmacy. See how this reshapes flu access in 2025.
Praxis Precision Medicines (NASDAQ: PRAX) surges 229% after breakthrough Phase 3 data in essential tremor
Praxis stock soared 229% on Phase 3 results for ulixacaltamide in essential tremor. Find out what this means for PRAX’s future and investor sentiment.
Gyre Therapeutics enrolls 272 patients in late-stage pirfenidone study targeting China’s pneumoconiosis crisis
Gyre Therapeutics completes enrollment of 272 patients in its Phase 3 pirfenidone trial for pneumoconiosis—find out how it could change treatment in China.
Merck’s once-daily DOR/ISL HIV therapy delivers sustained viral control and weight stability in Phase 3 results
Discover how Merck’s DOR/ISL HIV therapy preserves viral suppression and metabolic stability, signaling a new era in patient-centered HIV care.